Bio-Techne Corporation
Rank #217ValueTECH · Nasdaq · Healthcare
Bio-Techne Corporation (TECH) — Rank #217 by gross profitability (GP/assets 0.31) · ROE 8.6% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0000842023 · all metrics point-in-time as of the filing date.
About
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Show moreShow less
It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Industry
- Biotechnology
- Sector
- Healthcare
- State
- MN
- Filer Category
- Large accelerated filer
- Fiscal Year End
- June 30
- Website
- bio-techne.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2026-06-30filed 2026-08-24 | 2025-06-30filed 2025-08-22 | 2024-06-30filed 2025-08-22 | 2023-06-30filed 2025-08-22 |
|---|---|---|---|---|
| Revenue | 1,215.0 | 1,219.6 | 1,159.1 | 1,136.7 |
| Revenue growth (YoY) | -0.4% | 5.2% | 5.2% | 5.2% |
| Cost of revenue | 416.0 | 429.4 | 389.3 | 366.9 |
| Gross profit | 799.1 | 790.3 | 790.3 | 790.3 |
| Gross margin | 65.8% | 64.8% | 64.8% | 64.8% |
| Selling, general & administrative | 452.4 | 588.5 | 466.4 | 378.4 |
| Operating income | 251.9 | 102.3 | 206.7 | 298.9 |
| Operating margin | 20.7% | 8.4% | 8.4% | 8.4% |
| Interest expense | — | — | — | 11.2 |
| Pre-tax income | 240.7 | 98.5 | 185.7 | 338.7 |
| Income tax expense | 58.8 | 25.1 | 17.6 | 53.2 |
| Net income | 181.8 | 73.4 | 168.1 | 285.3 |
| Net margin | 15.0% | 6.0% | 6.0% | 6.0% |
| EPS (basic) | $1.17 | $0.47 | $1.07 | $1.81 |
| EPS (diluted) | $1.16 | $0.46 | $1.05 | $1.76 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?